Why UnitedHealth Isn’t Done Yet

UnitedHealth Group (NYSE: UNH) saw its stock surge 8% on September 9, 2025, after the company reported it’s on track to meet its Medicare Advantage enrollment targets. This was a relief for investors who had been worried the insurer might miss these critical numbers amid ongoing operational challenges.

Why does this matter so much? Medicare Advantage enrollment directly impacts UnitedHealth’s profitability – the quality of plans enrollees choose affects the company’s bottom line through government bonuses and margin differences.

See, this isn’t just a dead cat bounce. While UNH certainly isn’t out of the woods yet, this wasn’t just any minor positive news. The Medicare Advantage business is core to UNH’s strategy, and enrollment fears had been weighing heavily on investor sentiment. But here’s the thing – the stock had been beaten down so severely that even modest good news is likely to create significant upside moves. The stock was trading at levels far below where it was just months ago, at around $600.

The rebound rally has not only started, but it’s also touching 50% gains from the lows of under $240 seen just last month, and it could take the stock back to levels past $600. That being said, if you seek an upside with less volatility than holding an individual stock, consider the High Quality Portfolio. It has comfortably outperformed its benchmark—a combination of the S&P 500, Russell, and S&P MidCap indexes—and has achieved returns exceeding 91% since its inception. Separately, see – Oracle Stock To $900

Pixabay

The Math Behind The $600 Levels

The valuation argument is straightforward. UNH currently trades at approximately 0.8 times revenue versus its historical five-year average of 1.4 times. If the multiple expands back toward 1.4x as operational issues normalize, you’re looking at significant upside – potentially to the $600+ range.

Why might this normalization happen? UNH will likely pursue several margin improvement strategies:

• Cost-cutting initiatives across operations
• Focus on higher-margin products
• Premium increases where market conditions allow
• Better medical cost management

But, this isn’t a quick trade – it’s about patience. The path back to historical valuations will likely take time and won’t be smooth. There will be bumps, regulatory challenges, and ongoing medical cost pressures.

The key risks remain:

• Rising medical costs continuing to squeeze margins
• Regulatory scrutiny of Medicare Advantage practices
• Competition in core markets
• Potential policy changes affecting healthcare reimbursements

You may want to buy UNH at the next dip, but remember that investing in a single stock, no matter how promising, is risky. As an alternative, consider the Trefis Reinforced Value (RV) Portfolio, which has outperformed its all-cap stocks benchmark (combination of the S&P 500, S&P mid-cap, and Russell 2000 benchmark indices) to produce strong returns for investors. Why is that? The quarterly rebalanced mix of large-, mid- and small-cap RV Portfolio stocks provided a responsive way to make the most of upbeat market conditions while limiting losses when markets head south, as detailed in RV Portfolio performance metrics.

Bottom line

UNH appears positioned for significant recovery, but it requires conviction and patience. The stock has the potential to nearly double from current levels as operational metrics improve and valuation multiples normalize. The 50% move since early August suggests investors are starting to regain confidence, but the real test will be sustained execution over the coming quarters. For investors willing to ride through the inevitable volatility, the risk-reward proposition looks compelling at current levels.

Invest with Trefis Market-Beating Portfolios

See all Trefis Price Estimates